Christophe Queva

Company: Ovid Therapeutics Inc.

Job title: Chief Scientific Officer

Seminars:

Leveraging Oncolytic Viruses to Overcome the Challenges of the Immunosuppressive Tumor Microenvironment 11:15 am

Outlining the key factors that enable effective oncolytic virus entry and replication in GBM cells Using engineered transgenes or payloads to target and disrupt the immunosuppressive tumor microenvironment Overcoming immunosuppression using oncolytic viruses to counteract the challenges posed by GBM’s immune-resistant environmentRead more

day: Conference Day 1